胸水肿瘤标志物检测对肺癌所致胸腔积液的诊断价值  

Detection of Pleural Effusion Tumor Markers in the Diagnosis of Pleural Effusion Caused by Lung Cancer

作　　者：黄河[1] 李肇暖[1] 郑惠兰[1] HUANG He;LI Zhao-nuan;ZHENG Hui-lan(Department Laboratory,the Second Hospital of Sanming City,Sanming,Fujian Province,366000 Chin)

机构地区：[1]三明市第二医院检验科,福建三明366000

出　　处：《中外医疗》2018年第18期169-171,共3页China & Foreign Medical Treatment

摘　　要：目的研究肺癌所致胸腔积液临床诊断中进行胸水肿瘤标志物检测的价值。方法方便选择2015年1月—2018年1月该院肺癌所致胸腔积液患者50例,全部患者均接受胸水肿瘤标志物癌胚抗原(CEA)、癌抗原125(CA125)、神经原特异性烯醇化酶(NSE)、细胞角蛋白19片段(CYFRA 21-1)4项检测,分析检测结果。结果肺腺癌患者CEA、CA125为(407.93±111.12)μg/L、(1 144.45±1 360.42)U/mL,高于肺鳞癌(146.36±68.49)μg/L、(562.19±118.74)U/mL以及肺小细胞癌(204.63±81.59)μg/L、(462.79±78.45)U/mL,肺鳞癌CYFRA 21-1(86.59±34.22)ng/mL高于肺腺癌(27.15±13.05)ng/mL、肺小细胞癌(10.48±5.30)ng/mL,肺小细胞癌NSE(127.89±50.01)ug/mL高于肺腺癌(27.36±10.63)ug/mL、肺鳞癌(9.59±3.62)ug/mL;胸腔积液标本CEA、CA125、CYFRA21-1、NSE指标结果 (274.60±357.45)μg/L、(784.18±115.40)U/mL、(40.05±15.79)ng/mL、(49.90±20.46)μg/mL,高于血清(41.18±15.26)μg/L、(125.78±68.29)U/mL、(11.22±5.16)ng/mL、(24.75±3.18)μg/mL(t=96.321 4、80.157 2、26.301 8、31.027 5,P<0.000)。结论胸水肿瘤标志物4项检测对肺癌所致胸腔积液的诊断价值优于血清标志物,通过胸水肿瘤标志物检测能够协助临床区分癌症具体类型,实现胸腔积液的更准确诊断。Objective This paper tries to study the value of pleural effusion tumor markers in clinical diagnosis of pleural effusion caused by lung cancer. Methods 50 patients with pleural effusion caused by lung cancer in this hospital from January 2015 to January 2018 were selected conveniently. All patients received CEA, CA 125, neurogenic specific encephalitis markers. The four tests of alcoholase（NSE） and cytokeratin 19 fragment（CYFRA 21-1） were performed and the results were ana lyzed. Results The CEA and CA125 in patients with lung adenocarcinoma were（407.93±111.12）μg/L,（1 144.45±1 360.42）U/mL,higher than those in squamous cell carcinoma（146.36±68.49） μg/L,（562.19±118.74）U/mL, and lung small cell carcinoma（204.63±81.59）μg/L,（462.79±78.45）U/mL, lung squamous cell carcinoma CYFRA 21-1（86.59±34.22）ng/mL was higher than lung adenocarcinoma（27.15±13.05）ng/mL, small cell lung cancer（10.48±5.30）ng/mL, NSE（127.89±50.01）μg/mL was higher than that of lung adenocarcinoma（27.36±10.63） ug/mL, lung squamous cell carcinoma（9.59±3.62）μg/mL. Pleural effusion specimens CEA, CA125, CYFRA21-1, NSE index results（274.60±357.45）μg/L,（784.18±115.40）U/mL,（40.05±15.79）ng/mL,（49.90±20.46）μg/mL, higher than serum（41.18±15.26）μg/L,（125.78±68.29）U/mL,（11.22±5.16）ng/mL,（24.75 ±3.18）μg/mL（t=96.321 4, 80.157 2, 26.301 8, 31.027 5, P〈0.000）. Conclusion Four items of pleural effusion tumor markers are superior to serum markers in the diagnosis of pleural effusions caused by lung cancer. The detection of pleural effusion tumor markers can help distinguish clinical cancer types and achieve more accurate diagnosis of pleural effusions.

关 键 词：肺癌 胸腔积液 胸水 肿瘤标志物 检测 

分 类 号：R734[医药卫生—肿瘤]